申请人:Barden Christopher J.
公开号:US20100137388A1
公开(公告)日:2010-06-03
The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R
1
and R
2
represent hydrogen, tetrazole, or alkyltetrazole, respectively (with the restriction that if R
1
is not hydrogen, R
2
must be, and vice versa); R
3
represents e.g., benzyl, phenyl optionally substituted, biphenyl, napthyl, N-phenylcarboxamido, etc., R
4
represents e.g. carboxylic acid, or its alkyl esters, or a bioisoteric equivalent thereof, etc.; R
5
represents e.g. hydrogen, carboxylic acid, etc.] in particular, medicine which is useful as therapeutic and/or protective drugs for infectious and/or inflammatory diseases. Other relevant compounds are also provided.
本发明提供了一种治疗方案,其特点在于将抗生素与药用组合物共同使用或组合,其中药用组合物的前体抗生素活性成分是由式[I]所表示的化合物或其药学上可接受的复合物;[其中X表示氧、硫、NH或N-烷基;R1和R2分别表示氢、四唑或烷基四唑(限制条件是如果R1不是氢,则R2必须是氢,反之亦然);R3表示例如苄基、苯基可选择取代、联苯基、萘基、N-苯基羧酰胺等;R4表示例如羧酸、其烷基酯或其生物等价物等;R5表示例如氢、羧酸等],特别是对于感染和/或炎症疾病有用作为治疗和/或保护药物的药物。还提供了其他相关化合物。